Willingness and ability to consent (and assent if under age 18) for self to participate in study
Patients (at National Cancer Institute [NCI] Community Oncology Research Program [NCORP] Institutions only) must be offered the opportunity to participate in the S1207-E01 Behavioral and Health Outcomes study (BAHO); NOTE: patients who have already started endocrine therapy are eligible for the BAHO study
Patients must be offered the opportunity to participate in specimen banking
Patients must be offered the opportunity to participate in specimen banking
Patients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapy
Willingness and ability to consent to participate in study
A female is eligible to enter and participate in this study if the following apply:
Has any other reason(s) for the investigator to consider that the subject should not participate in the study.
Willing to agree that the local medical oncologist may be informed that patient has agreed to participate in the study
Patients must be geographically accessible and willing to participate in all stages of treatment
All patients have to agree to participate in the correlative study of sample collection for immune correlative assays in order to participate in the main study; however, if the sample cannot be obtained due to feasibility issues, the patient will be allowed to continue on treatment
Patients who are on active surveillance for untreated localized disease may not participate in this study
Participant is willing and able to participate for the duration of the study
Participates or intends to participate in another drug study (other than observational studies) during the study
Clinical judgment by the investigator that the patient should not participate in the study
Patients from outside of the United States may participate in the study
Patients unable to read/write in English are eligible to participate in the overall study but will not participate in the patient-reported outcome questionnaires throughout the trial.
Subjects willing to participate in the study for at least 8 months
Willingness and ability to consent for self to participate in study
Must have voluntarily agreed to participate and have signed the informed consent, and are willing to complete all study procedures.
Clinical judgment by the investigator that the patient should not participate in the study
Patients must give documented informed consent to participate in this study
Patient refusal to participate in randomization
Has given written consent to participate in the study.
Agree to participate in biopsy of metastatic lesion during the study at day 21
Willingness and ability to consent for self to participate in study
All patients must be willing and capable to provide informed consent to participate in the protocol
Patients must agree to participate and be able to understand and provide informed consent to participate in the trial
Must consent to participate in study I 03103: Roswell Park Cancer Institute (RPCI) Data Bank and Biorepository (DBBR)
Subject must be capable and reliable to participate in all study related procedures
Patients must be willing to participate in all stages of treatment
Patients in the expansion cohort must also agree to participate in the biomarker study. However, patients in the Melanoma KIT positive mutant subgroup, patients must agree to participate in the biomarker study and biopsies.
Patients must give documented informed consent to participate in this study
It is expected that five types of patients afflicted with EBV-associated lymphomas, lymphoproliferative disease or malignancies will be referred and will consent to participate in this trial; these are:
Willingness to participate in rigorous neurocognitive evaluations at baseline and serially following treatment
All patients must be willing and capable to provide informed consent to participate in the protocol
Patients must be willing to participate in all stages of treatment
Patients must be geographically accessible and willing to participate in all stages of treatment
Willing and able to consent for self to participate in study
Patients who have demonstrated resistance to platinum agents (e.g. oxaliplatin, cisplatin) are not eligible to participate in this study
Patients for whom it is not in the best interest to participate in the study, in the opinion of the treating investigator
Any other reason the investigator considers the patient should not participate in the\n             study
Signed informed consent to participate in the study, including participation in the expansion cohort after safety of enzalutamide and gemcitabine and cisplatin have been established, must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information
Patients with and without FLT3 mutations will be eligible to participate
Patients must give documented informed consent to participate in this study
Willing to participate in associated correlative science biomarker study
Willing to participate in associated correlative science biomarker study
Patients must be offered the opportunity to participate in the ultra pure Circulating Tumor Cells (upCTCs) study
Patients must be offered the opportunity to participate in specimen banking as outlined
All patients must be willing and capable to provide informed consent to participate in the protocol
Patients must be offered the opportunity to participate in specimen banking for future use
Written informed consent to participate in this study before the performance of any study-related procedure
Willingness and ability to consent for self to participate in study
Donor does not consent to or is unable to participate in this trial
Patients already receiving treatment with FOLFIRINOX +/- trastuzumab may participate in the study and have their data collected retrospectively if they met inclusion criteria at the start of therapy and sign consent for study participation moving forward
Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information
All patients must be willing and capable to provide informed consent to participate in the protocol
Mayo Clinic Arizona only: Willing to participate in associated biobanking study, 919-04; the patient must sign consent to enroll onto the mandatory companion biobanking study in order to participate in this treatment study
Mayo Clinic Rochester and Florida only: Willing to participate in associated biobanking study, 521-93; the patient must sign consent to enroll onto the mandatory companion biobanking study in order to participate in this treatment study
Agree to participate in research blood collection at 4 different time periods (20 ml = 4 teaspoons)
Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information
All patients must be willing and capable to provide informed consent to participate in the protocol
Consent to participate in Data Bank and BioRepository (DBBR) (Roswell Park Cancer Institute [RPCI] only)
Any other reason the investigator considers the patient should not participate in the study
Ability to participate in the clinical study for a minimum of at least 2 cycles (6 weeks).
Patients must give documented informed consent to participate in this study
Patients should not participate in any other therapeutic investigational study while taking part in this study
Willing and able to give informed consent and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.
Written informed consent to participate in this study before the performance of any study-related procedure
Willingness to provide the blood specimens as required by the protocol; please note that the willingness to participate pertains only to the patient and does not factor in the institutionâ€™s ability to participate in any part of the translational component
Eligible to give informed consent to participate in the study.
PART I: Participants who have no language barrier, are cooperative, and can give informed consent before entering the study after being informed of the medications and procedures to be used in this study may participate
PART II: Participants who have no language barrier, are cooperative, and can give informed consent before entering the study after being informed of the medications and procedures to be used in this study may participate
Clinical judgement by the investigator that the patient should not participate in the study
Subjects can participate in the study if in the opinion of the investigator it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data.
Patient desires not to participate in the study.
Only one subject per household may participate
Males are not permitted to participate
KEY INFORMANT: Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team
KEY INFORMANT: Unwilling to participate
Willing to consent to randomization and able to participate in the study
FOCUS GROUPS:\r\n* Has a household member who has already participated (or agreed to participate)
Those mentally or physically unable to read the consent form or other study materials and/or participate in the consent and engagement with the CaringGuidance program; women who have been hospitalized for mental health issues or substance abuse in the past year are ineligible
Have parental consent to participate
Patients must be offered the opportunity to participate in specimen banking for future research
Patients who are incompetent for interview (documented diagnosis of active psychosis or dementia) or unable to provide informed consent as assessed by the interviewer; or too sick to participate, as judged by a member of the research team or the exercise physiologist, or have been treated for another cancer
Significant uncontrolled psychiatric or other co-morbid disease, which the primary oncologist believes prohibits the ability to participate in study procedures
Adult caregivers (> 18 years) of patients who have agreed to participate in the study
(Physician participation) willing to participate in the study
Refusal to participate in the study
Able to participate safely in all program sessions
Cognitively able to consent to participate
Excluded patients will be allowed to participate in the trial on an observational basis only
Be mentally and physically able to participate in the study
PATIENT ONLY: Having a spouse/romantic partner (including same-sex) and who is willing to participate
Patient refusal to participate in randomization
Patients who are incompetent for interview (documented diagnosis of active psychosis or dementia) or unable to provide informed consent as assessed by the interviewer; or too sick to participate, as judged by a member of the research team
Children aged 14-17 will assent to participate in the research study by signing a separate assent form
INCLUSION CRITERIA FOR PARENTS: Cognitively able to participate in interactive interviews
EXCLUSION CRITERIA FOR PARENTS: Parent is cognitively or physically unable to participate in interactive interview
Physician verification of ability to participate in the intervention
Physically and cognitively able to participate in the study as determined by the investigators
HSCT CGs: Physically and cognitively able to participate in the study as determined by the investigators
Physically and cognitively unable to participate in the study as determined by the investigators
HSCT CGs: Physically and cognitively unable to participate in the study as determined by the investigators
Participants must self-identify as female; thus only women with breast cancer will be invited to participate in this study
Patients that consent to participate
Have a co-survivor (friend or family member) willing to participate in this research study
Willing to participate in yoga therapy for twelve weeks if randomized to intervention group
Unwilling to participate in yoga therapy for twelve weeks if randomized to intervention group
Willing to come to MD Anderson (MDA) for the therapy sessions; or willing to participate in the therapy sessions at their homes and live within a 45 minute drive of MDA main campus; or can participate in the therapy sessions from one of MDAâ€™s Regional Care Centers
Caregivers with children (patients) who are younger than 10 years of age may be eligible to participate even though their children are too young to assent or participate themselves
Subject must be capable and reliable to participate in all study related procedures
Patients who refuse to participate
Be willing to provide written informed consent to participate in the study which includes several clinical evaluations, provide access to medical records/primary care physician (PCP), and allow all interviews and PSST therapy sessions to be audiotaped.
PATIENTS: Willingness to participate in all study activities including data collection
PATIENTS: Willing to identify a FCG (immediate or extended family member) to participate
FCGs: Willingness to participate in study activities including data collection
Only requirement for organ function is for patients to have competency to consent and participate in the study; in the arm of the study which requires patients to have olfactory dysfunction before enrollment, an UPSIT score will be used to identify these patients
Significant psychiatric or other co-morbid disease, which the treating clinician believes prohibits the patientâ€™s ability to participate in the informed consent procedures
Patients who will be hospitalized to undergo first-time autologous or allogeneic BMT will be given the opportunity to assent/consent and participate in the study; with his/her permission, the patient will also be provided with their own iPadÂ® BMT Roadmap information system to use; qualitative interviews will be conducted in patients with their assent/consent
Ability to safely participate in outpatient rehabilitation program
Unable to safely participate in outpatient rehabilitation
Too sick to participate, as determined by the treating oncologist
AYA PATIENTS ONLY: Patients that are not able to participate in the study due to their medical condition and/or treatment regimen will be excluded; such exclusion will be determined by the patients' treating oncologist in conjunction with patients' family members
All couples co-habiting for at least 3 years with current partner who is willing to participate in study
Cognitively able to participate in interactive interviews
Patient refusal to participate (any age), or parental refusal to participate for patients less than 18 years of age
Cognitively or physically unable to participate in interactive interview
Patient is willing to participate in this study
Participants with serious or unstable illness, as determined by study physicians and clinicians, may be deemed unfit to participate
Physically unable to participate in the study
have the permission of their oncologists to participate.
Willing to consent to participate
Any woman currently pregnant will not be eligible, but may participate 3 or more\n             months after the end of her pregnancy if the study is still ongoing
Have a stable partner for six months who is willing to participate
Able and willing to participate in an art therapy session at Maroone Cancer Center
Mentally and physically able to participate and complete surveys over the phone
Spouses/partners could not participate if the patient refused participation
Become unable to participate in a fully app and web-based intervention trial
Physician approval to participate in intervention
Excluded patients will be allowed to participate in the trial on an observational basis only
Patient refusal to participate in randomization
Patients must be offered the option to participate in the Diet and Lifestyle Substudy
Women who are using postmenopausal hormones, and are planning to continue the same regimen through the study intervention are eligible to participate
Individuals who are unable to participate in cycling due to musculoskeletal limitations.
Willing to participate in a weekly behavioral modification group phone call for first 3 months and every 2 weeks for the second 3 months
Willing to participate in a weekly behavioral modification group phone call for 3 months
Voluntarily agree to participate and read the informed consent documents
Multiple children from the same family are eligible to participate in the study
Patients who are being screened for the therapeutic clinical trial will also be approached for participation into the optional sub-study evaluating sociobiological response to stress; refusal to participate in the sub-study will not impact the patientâ€™s eligibility to participate in the therapeutic intervention\r\n* Should a patient consent to the optional sub-study, the patient may proceed with the optional baseline interventions for the optional sub-study as outlined within the protocolâ€™s study calendar
Multiple members of the same household cannot participate.
Willing to participate in all study components
Subjects consent to participate in the trial
LGBT SUB-STUDY: Participants who complete the screener, are willing to participate in a longitudinal study for one year, and who self-identify as lesbian, gay, bisexual or transgender will be eligible to participate in the cohort study
Patients must give written informed consent to participate in this study before the performance of any study-related procedure.
PARTICIPANTS: Are willing to participate in a study about health behaviors involving nutrition or CRC screening
Ability to participate fully in research elements for the duration of the trial.
general conditions in which subjects are not suitable to participate in the study
Patients who refuse to participate
Subjects who require sedation to participate will be excluded
Subjects who refuse to participate, or demonstrate inability to give informed consent
Individuals who have any of the following will not be eligible to participate:
Vulnerable patient populations:\r\n* Patients unable to participate in the consent process (children and neonates)
Willingness to participate in collection of pharmacokinetic samples
Patients who do not wish to participate
Subjects must be eligible for and willing to participate and sign consent for National Cancer Institute (NCI) protocol 08-C-0079: Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1, for the clinical evaluation necessary for this study
Subjects will be selected on the basis of their willingness and ability to participate and on their likelihood of completing the study
Any patient under age 18 may only participate in 3T imaging
Patients under the age of 18 may not participate in 7T imaging
Subjects who refuse to participate, or demonstrate inability to give informed consent
Patients who refuse to participate
Willing and able to consent and participate in the study.
Ability to travel to appointments and willingness to participate in this study
Patients who have been referred for CTU will also be invited to participate in the study
Patients who refuse to participate
Subjects who are willing to participate
Participant is willing to participate in the educational component of this project
OHSU Radiation Medicine department has agreed to participate as pilot department for this project; all active Radiation Medicine providers are requested to participate in the training; providers have the option to not participate
CAREGIVERS: Adult caregivers (> 18 years) of patients who have agreed to participate in study
Patients who do not verbally, written, or electronically consent to participate (usability test and RCT)
Those who do not wish to participate
Patients who refuse to participate in the study
Willingness and ability to consent for self to participate in study
